A Phase 2 interventional study of ABP-450 and Placebo in Cervical Dystonia, sponsored by AEON Biopharma, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-14.
Sponsored by AEON Biopharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Torticollis with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Torticollis · United States.
Among the 57 studies in Torticollis with a site in United States, this one is the 15th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 2, and was the 44th registered.
121 studies on the registry are indexed under Torticollis; 18 are open to participants now.
Browse Torticollis studies →7 of the 57 studies in Torticollis with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–89
Vima Therapeutics · Sites in United States, Canada
Ages 18–70
Ipsen · Sites in United States, Czechia, France and 5 more countries
Ages 18–80
University of Minnesota · Sites in United States
Ages 30+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Torticollis studies recruiting now, 4 (33%) set no upper age limit and 4 (33%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 7 · Phase 4 5
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 50 across 76 interventional studies indexed under Torticollis.
Median enrollment 45 across the 38 interventional studies, 44 across the 19 observational. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 57 have an industry lead sponsor. The 10 most frequent:
AEON Biopharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
AEON Biopharma, Inc. has 2 studies filed under Torticollis — fewer than ten, so there is no comparison to draw.
7 of the studies in Torticollis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07111663Vima TherapeuticsAn Observational Study of Individuals With Isolated Dystonia | 2026-11 |
| NCT07245615University of MinnesotaEffect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical Dystonia | 2026-12-31 |
| NCT07304089Vima TherapeuticsA Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia | 2027-03 |
| NCT06937931IpsenA Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | 2027-03-26 |
| NCT07140874University of FloridaZinc as an Adjunctive Therapy for Cervical Dystonia | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 57 studies in Torticollis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites in the United States. Study subjects will be divided evenly across a low dose group, a medium dose group, a high dose group, and a placebo group for one treatment cycle.
This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites in the United States. Study subjects will be divided evenly across a low dose, a medium dose group, a high dose and placebo group for one treatment cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A clinical diagnosis of cervical dystonia (ie, spasmodic torticollis) defined by:
Exclusion Criteria:
For pre-treated patients only: The patient's most recent injection with botulinum toxin exceeding the number of units specified as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
Drug: ABP-450
ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
Drug: ABP-450
ABP-450 High Dose - Intramuscular injections into affected neck muscles.
Drug: ABP-450
Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
Drug: Placebo
ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Also known as: prabotulinumtoxinA
0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
Also known as: 0.9% sodium chloride, saline
Number of Participants With Treatment-Related Serious Adverse Events
The primary safety endpoint will be the number of participants with treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with placebo, ABP-450 (low dose), ABP-450 (medium d dose), or ABP-450 (high dose).
Time frame: Baseline up to 20 Weeks
Mean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 4
The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).
Time frame: Baseline to Week 4
Mean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.
Time frame: Baseline to Week 4
Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.
Time frame: Baseline to Week 4
Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.
Time frame: Baseline to Week 4
Mean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 4
The PGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.
Time frame: Baseline to Week 4
Mean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 4
The CGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.
Time frame: Baseline to Week 4
Participants were recruited at 25 sites in the U.S. between March 29, 2021 and July 11, 2021.
| Milestone | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Started | 15 | 15 | 16 | 15 |
| Randomized but not dosed | 1 | 1 | 0 | 0 |
| Treated | 14 | 14 | 16 | 15 |
| Safety analysis set | 14 | 14 | 16 | 15 |
| Full analysis set | 14 | 14 | 16 | 15 |
| Modified full analysis set | 14 | 14 | 14 | 15 |
| Completed | 11 | 9 | 13 | 10 |
| Not completed | 4 | 6 | 3 | 5 |
| Withdrew: Lack of efficacy | 3 | 4 | 1 | 4 |
| Withdrew: Other reasons | 1 | 2 | 2 | 1 |
The primary safety endpoint will be the number of participants with treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with placebo, ABP-450 (low dose), ABP-450 (medium d dose), or ABP-450 (high dose).
| Participants | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Number of Participants With Treatment-Related Serious Adverse Events | 0 | 0 | 0 | 0 |
The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).
| score on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 4 | 3.57 ± 2.67 | 14.01 ± 2.63 | 11.28 ± 2.70 | 9.92 ± 2.54 |
The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.
| score on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4 | 1.02 ± 1.11 | 4.53 ± 1.09 | 4.24 ± 1.14 | 2.62 ± 1.06 |
The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.
| score on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4 | 1.27 ± 1.10 | 3.56 ± 1.05 | 3.58 ± 1.08 | 3.69 ± 1.02 |
The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.
| score on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4 | 1.91 ± 0.91 | 5.89 ± 0.91 | 2.94 ± 0.97 | 3.45 ± 0.87 |
The PGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.
| units on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 4 | 4.0 ± 1.11 | 2.6 ± 0.31 | 2.2 ± 0.32 | 2.7 ± 0.30 |
The CGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.
| units on a scale | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Mean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 4 | 3.9 ± 0.33 | 2.3 ± 0.32 | 2.0 ± 0.33 | 2.7 ± 0.31 |
Collected over Up to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| ABP-450 - 150U | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| ABP-450 - 250U | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| ABP-450 - 350U | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Event | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|---|
| Neck painMusculoskeletal and connective tissue disorders | 3/14 | 1/14 | 2/16 | 1/15 |
| DysphagiaGastrointestinal disorders | 0/14 | 0/14 | 2/16 | 3/15 |
| Muscular WeaknessGastrointestinal disorders | 0/14 | 2/14 | 1/16 | 1/15 |
| HeadacheNervous system disorders | 1/14 | 2/14 | 2/16 | 1/15 |
| TorticollisMusculoskeletal and connective tissue disorders | 0/14 | 0/14 | 1/16 | 2/15 |
| COVID-19Infections and infestations | 0/14 | 1/14 | 1/16 | 2/15 |
| NauseaGastrointestinal disorders | 0/14 | 0/14 | 2/16 | 0/15 |
| Upper respiratory tract infectionInfections and infestations | 0/14 | 0/14 | 2/16 | 0/15 |
| Head discomfortNervous system disorders | 0/14 | 1/14 | 0/16 | 0/15 |
| Injection site painGeneral disorders | 1/14 | 1/14 | 0/16 | 0/15 |
Two patients were excluded from the analysis due to a change in their background medication.
| Age, Continuous(years) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| Mean | 59.3 ± 11.06 | 55.8 ± 12.97 | 54.6 ± 13.61 | 55.3 ± 11.39 | 56.2 ± 12.09 |
| Sex: Female, Male(Participants) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| Female | 7 | 7 | 13 | 12 | 39 |
| Male | 7 | 7 | 1 | 3 | 18 |
| Race (NIH/OMB)(Participants) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| White | 13 | 14 | 11 | 14 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 2 |
| Previous treatment with BOTOX®(Participants) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| Count of participants | 10 | 9 | 11 | 10 | 40 |
| Duration of Cervical Dystonia(years) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| Mean | 14.83 ± 11.134 | 14.58 ± 10.799 | 7.36 ± 6.464 | 11.53 ± 7.175 | 12.26 ± 9.421 |
| Baseline TWSTRS-Total Score(units on a scale) | Placebo | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|---|
| Mean | 39.68 ± 7.525 | 44.30 ± 6.093 | 42.20 ± 11.585 | 43.62 ± 9.847 | 42.47 ± 8.962 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in a publication outside posting the results in clinicaltrials.gov.
Ran from Mar 2021 to primary completion in Jul 2022, 15 months.
Results were first posted in Feb 2024, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prabotulinumtoxin A
AEON Biopharma, Inc.